Zohydro ER Faces FDA Rejection


Zohydro ER Faces FDA Rejection

The Food and Drug Administration (FDA) is now opposing the Zohydro ER made by Zogenix Inc. which is stronger and new version of hydrocodone.

The drug was voted very low i. e. 11-2 with one nonparticipation. FDA received the suggestion of government pain expert panel over their rejection since the painkiller was reported to cause high levels of abuse.

Zogenix Inc. is based San Diego who developed the Zohyro ER capsules to cure average to chronic pains. The rejection has emerged as a vital setback for the drug maker since the trades of the drug have been stopped in wake of the news.

However, the FDA will make a final decision about the drug in March 2013 when it will tell whether the drug is safe for use. And if the drug gets the nod from the health officials, US will get its first pure hydrocodone painkiller while those in market as of now are of lower strength.

"There is a documented patient need for an extended-release hydrocodone medicine without acetaminophen. We remain confident in the measures we have proposed to support safe use of Zohydro ER", said Stephen Farr, the President and Chief Operating Officer of Zogenix.

The drugs with hyrocodone and other combinations come under Schedule III drugs while Zohydro ER shall be classified as schedule II drug as it is more powerful.

Latest News

Clean Energy Research to get Historic Investment during the United Nations
Investors Keenly Wait for OPEC Meeting; Oil Prices Move Up a Little
Amazon Testing Drones in Multiple International Locations
NextEra Agrees to Sell Two Texas Power Plants to Luminant
China’s Yuan Could be Named a Reserve Currency by the IMF
Rupert Murdoch Tweets Tribune Probably Selling Los Angeles Times
Black Friday Shopping “Uninspiring” in Brick and Mortar Stores; Shopping Trends
U.S. Crude Drops Further Due to Surplus Supply
CVC and CPPIB Outbid Others for a Possible Deal to Buy Petco for $4.7 Billion
US Government All Set to Introduce a New Law for Americans “Seriously Delinquent
Reportedly Pfizer Plans to Acquire Allergan in a Deal of $150 Billion or More
In October Most States Experienced a Drop in Unemployment Rate